High-dose treosulfan in conditioning prior to hematopoietic stem cell transplantation.
BACKGROUND
Despite the marked development in the field of preparative regimens prior to hematopoietic stem cell transplantation (HSCT) over the last decade, the search for a superior conditioning agent is still continuing. In view of the literature reports, treosulfan (TREO), a structural analog of busulfan (BU), appears to be a promising candidate in terms of myeloablative, immunosuppressive and antimalignancy effects as well as low organ toxicity.


METHODS
The article focuses on pharmacological activity, pharmacokinetics and toxicity of TREO. Compressed description of the drug-based conditioning prior to HSCT is also presented. Finally, TREO and BU characteristics are compared. Specific information of TREO concerning pediatric and adult patients is provided throughout the whole paper. The data refer predominantly to the publications, in majority from the last 10 years.


RESULTS
According to our best knowledge, the paper is the first such comprehensive review on TREO, especially in terms of its application in pediatric HSCT.


CONCLUSIONS
TREO offers a great potential as a conditioning agent prior to HSCT but further investigations of the drug are warranted to clearly verify its advantages. However, we expect TREO to be registered as a novel conditioning agent in the near future.
Główka
Franciszek K
FK
Department of Physical Pharmacy and Pharmacokinetics, Poznan University of Medical Sciences, Poznań, Poland. glowka@ump.edu.pl
Romański
Michał
M
Wachowiak
Jacek
J
D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics; D002066:Busulfan / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000737:chemistry / Q000493:pharmacokinetics; D002986:Clinical Trials as Topic; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D019653:Myeloablative Agonists / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics; D019172:Transplantation Conditioning
D018906:Antineoplastic Agents, Alkylating; D019653:Myeloablative Agonists; C018404:treosulfan; D002066:Busulfan